|
|
Innocan Pharma Corporation is an Israel-based pharmaceutical company active in the medical cannabis industry. It operates through three distinct operating segments: Research, Development, Marketing, Distribution and sales of InnoCan-branded over the counter (OTC) pharmaceutical products; Research and Development of Non-pharmaceutical products for third parties and Research and Development of hydrogels containing liposomes intended for licensing or sale to third party pharmaceutical corporations for manufacturing, distribution and sales. The Company is developing an OTC topical treatments product line and new platform to facilitate the targeted controlled administration of cannabinoids via injection. |
|
|
| 2021 | 2022 | Delta | | Cannabidiol-integrated Pharmaceuticals | 0.25 | 100% | 3.33 | 100% | +1255.72% |
| CAD in Million |
|
|
|
| 2022 | | United States | 3.15 | 94.5% |
| United Kingdom | 0.11 | 3.2% |
| Rest of the World | 0.08 | 2.3% |
| CAD in Million |
|
|
|
| Vote  | Quantity | Free-Float | Company-owned shares | Total Float |
| Stock A |
1 |
249,728,111 |
177,835,968 |
71.2% |
0 |
0.0% |
71.2% |
|
|
|
| Name | Equities | % | | Solsken Ltd. | 48,595,875 |
19.6% | | Yoram Druker | 12,201,000 |
4.91% | | Ron Abraham Mayron | 5,160,000 |
2.08% | | Iris Or Gabi Bincovich | 2,859,750 |
1.15% | | Eyal Flom | 1,837,500 |
0.74% | | PP-Asset Management GmbH | 528,000 |
0.21% | | Nelson Halpern | 300,000 |
0.12% | | Peter David Bloch | 0 |
- | | Ralph C. L. Bossino | 0 |
- | | Nir Avram | 0 |
- |
|
| Company contact information |
|
|
|
|
Sector Other Pharmaceuticals
Connections : InnoCan Pharma Corporation |
Google
Twitter
Facebook
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
